Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.92 USD | +1.47% | -6.74% | -9.85% |
Apr. 25 | Transcript : Core Laboratories Inc., Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 24 | Earnings Flash (CLB) CORE LABORATORIES Reports Q1 Revenue $129.6M, vs. Street Est of $124.5M | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Business Support Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.85% | 736M | B+ | ||
+13.54% | 16.86B | A | ||
0.00% | 7.03B | - | - | |
-11.41% | 2.91B | B+ | ||
-6.89% | 2.85B | - | ||
-27.64% | 1.83B | - | - | |
-2.47% | 1.16B | - | ||
-6.63% | 1.07B | - | ||
-10.95% | 831M | - | ||
+0.83% | 761M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLB Stock
- Ratings Core Laboratories Inc.